
SNN Stock Forecast & Price Target
SNN Analyst Ratings
Bulls say
Smith & Nephew demonstrated positive underlying growth of 5.3%, with a notable increase of 15.9% when excluding the impacts from China, indicating resilience in its core markets. The company expects a stronger second half of the year, supported by improved operating leverage and cost efficiencies, with anticipated trading profit margins between 19.0% and 20.0% for 2025. Additionally, growth in key segments, including a 4.7% rise in hips and a 5.5% increase in orthopedics, underscores the firm’s robust performance in the U.S. market, despite challenges in international markets like China.
Bears say
Smith & Nephew's financial outlook appears challenging due to anticipated weaker revenue in Q1 FY25, influenced by factors such as fewer selling days, the impact of China Joint Repair volume-based pricing (VBP), and ongoing distributor inventory reductions. Additionally, the company expects further negative revenue impacts from VBP in its advanced wound therapy segment, alongside a return to normalized growth conditions that may still fall short of prior performance. The orthopedic segment, despite improving, exhibits a return on invested capital (ROIC) significantly below other business units, compounded by risks from evolving US healthcare reimbursement rates and persistent headwinds in the Chinese market.
This aggregate rating is based on analysts' research of Smith & Nephew and is not a guaranteed prediction by Public.com or investment advice.
SNN Analyst Forecast & Price Prediction
Start investing in SNN
Order type
Buy in
Order amount
Est. shares
0 shares